Viewing nowCombinationGlyan Duo Tablet 5/1000mg (Empagliflozin, Metformin Hydrochloride)
Empagliflozin Amorphous 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.

MFDS item code 202201391 · Approved 2022.04.04 · Insurance code 643705630
Improvement of glycemic control in adults with type 2 diabetes
This drug, by combining empagliflozin and metformin, is used to improve blood sugar control in adults with type 2 diabetes. It specifically aids in blood sugar management alongside dietary and exercise regimens. Furthermore, in patients with type 2 diabetes who do not have adequate blood sugar control and have cardiovascular disease, care must be taken to prevent cardiovascular events. Therefore, it should be used safely with guidance from professionals to effectively manage blood sugar and cardiovascular health.
The recommended dose of this drug is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose of 10 mg) and the patient's current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this drug from combination therapy with empagliflozin (total daily dose of 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this drug is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Interactions under Precautions for Use). This drug should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this drug, take it as soon as you remember. However, do not take a double dose at one time; if this happens, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is required for patients with mild renal impairment. Because this drug contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this drug is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see section 3. Patients Requiring Caution, item 1 under Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately (see section 2. Patients Who Must Not Take This Drug, item 2 under Precautions for Use). Elderly Patients For patients aged 75 years or older, renal function and the risk of volume depletion should be considered.
This medication is used for diabetes treatment and works by combining two components to control blood sugar. While taking this medication, there is a risk of a rare side effect called severe lactic acidosis, so caution should be taken, especially in patients with impaired renal function or severe infections and dehydration. Additionally, when taken with insulin or other diabetes medications, hypoglycemic symptoms may occur, so blood sugar changes should be closely monitored. Patients with moderate to severe renal impairment or certain acute illnesses, type 1 diabetes patients, and patients with acute heart failure should not use this medication. Before and after examinations using iodinated contrast agents, this medication should be discontinued, and resumed only once kidney function returns to normal. Regular monitoring of renal function and blood creatinine levels is required during treatment, especially for elderly patients or those with reduced renal function who need more frequent checks. This medication may cause side effects such as gastrointestinal disturbances, urinary tract infections, genital infections, and increased urination, so patients should consult healthcare professionals if symptoms occur. It is safer for women who are pregnant or may become pregnant or breastfeeding to avoid using this medication. Moreover, alcohol ingestion may increase the risk of lactic acidosis, so it is best to avoid it during treatment. Attention should be paid to hypoglycemic symptoms during the course of medication, and avoiding irregular meals or strenuous exercise is important. For patients scheduled for surgery or experiencing acute illnesses, temporarily suspending this medication and consulting healthcare providers is advised. This medication is not recommended for children and elderly patients should have dosage adjustments based on renal function. In case of overdose, immediate medical attention is required, especially if lactic acidosis is suspected, swift emergency treatment is necessary. Lastly, this medication should be stored out of the reach of children and kept in its original container for safety.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. The storage temperature should be maintained between 1 and 30 degrees Celsius at room temperature to preserve the medication’s effectiveness.
Brownish-yellow, bilaterally convex, oval-shaped film-coated tablet
30 tablets/box [(6 tablets/PTP x 5)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin Amorphous 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
CombinationEmpagliflozin Amorphous 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Empagliflozin Amorphous 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Empagliflozin Amorphous 25mg
Tablet · Prescription medication · Combination
Aprogen Pharmaceuticals Co., Ltd.
CombinationEmpagliflozin Amorphous 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Empagliflozin Amorphous 10mg
Tablet · Prescription medication · Combination
Aprogen Biosystems, Co., Ltd.
CombinationEmpagliflozin Amorphous 10mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationEmpagliflozin Amorphous 25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.